Abstract
Glutamate is the most abundant excitatory neurotransmitter in the brain and the ionotropic NMDA receptor is one of the major classes of its receptors, thought to play an important role in schizophrenia and mood disorders. The current systematic review summarized the evidence concerning the involvement of NMDA receptors in the pathophysiology of bipolar disorder. Genetic studies point to the genes encoding the NMDA 1, 2A and 2B subunits while neuropathological studies suggest a possible region specific decrease in the density of NMDA receptor and more consistently a reduced NMDA-mediated glutamatergic activity in patients with bipolar disorder in the frame of slower NMDA kinetics because of lower contribution of NR2A subunits. However the literature is poor and incomplete; future research is necessary to elucidate the mechanisms underlying bipolar disorder and its specific relationship to a possible NMDA malfunction and to explore the possibility of developing novel therapeutic agents.
Keywords: NMDA, glutamate, excitatory aminoacids, bipolar disorder, lithium, neurotransmitter, ionotropic NMDA receptor, schizophrenia, mood disorders, glutamatergic activity
Current Pharmaceutical Design
Title:The Possible Involvement of NMDA Glutamate Receptor in the Etiopathogenesis of Bipolar Disorder
Volume: 18 Issue: 12
Author(s): Konstantinos N. Fountoulakis
Affiliation:
Keywords: NMDA, glutamate, excitatory aminoacids, bipolar disorder, lithium, neurotransmitter, ionotropic NMDA receptor, schizophrenia, mood disorders, glutamatergic activity
Abstract: Glutamate is the most abundant excitatory neurotransmitter in the brain and the ionotropic NMDA receptor is one of the major classes of its receptors, thought to play an important role in schizophrenia and mood disorders. The current systematic review summarized the evidence concerning the involvement of NMDA receptors in the pathophysiology of bipolar disorder. Genetic studies point to the genes encoding the NMDA 1, 2A and 2B subunits while neuropathological studies suggest a possible region specific decrease in the density of NMDA receptor and more consistently a reduced NMDA-mediated glutamatergic activity in patients with bipolar disorder in the frame of slower NMDA kinetics because of lower contribution of NR2A subunits. However the literature is poor and incomplete; future research is necessary to elucidate the mechanisms underlying bipolar disorder and its specific relationship to a possible NMDA malfunction and to explore the possibility of developing novel therapeutic agents.
Export Options
About this article
Cite this article as:
Konstantinos N. Fountoulakis , The Possible Involvement of NMDA Glutamate Receptor in the Etiopathogenesis of Bipolar Disorder , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958585
DOI https://dx.doi.org/10.2174/138161212799958585 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Genetics and Therapies for GM2 Gangliosidosis
Current Gene Therapy The Role of PrP in Health and Disease
Current Molecular Medicine The Role of Oligodendrocytes in the Molecular Pathobiology and Potential Molecular Treatment of Cervical Spondylotic Myelopathy
Current Medicinal Chemistry Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety Altered Functional Connectivity of the Marginal Division in Alzheimer’s Disease
Current Alzheimer Research The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design The Effects of the Endocrine Disruptors Dithiocarbamates on the Mammalian Ovary with Particular Regard to Mancozeb
Current Pharmaceutical Design Relationship Between Na<sup>+</sup>, K<sup>+</sup>-ATPase and NMDA Receptor at Central Synapses
Current Protein & Peptide Science The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Impact of HIV on Regional & Cellular Organisation of the Brain
Current HIV Research The Effect of CB1 Antagonism on Hepatic Oxidative/Nitrosative Stress and Inflammation in Nonalcoholic Fatty Liver Disease
Current Medicinal Chemistry EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research